This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DiaDexus, Inc. Advances Clinical Validation Program For PLAC® Test For Lp-PLA2 Activity

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it is advancing its clinical program to support the submission of the company’s PLAC® Test for Lp-PLA 2 Activity. This important next step in the regulatory clearance process follows a recent pre-submission meeting with the U.S. Food and Drug Administration (FDA).

diaDexus has partnered with a large longitudinal cardiovascular disease study to validate the PLAC Test for Lp-PLA 2 Activity. It is anticipated that the clinical study sample analysis will be initiated prior to the end of the first quarter of 2014.

“We now have further clarity on our path forward to potential FDA clearance in the United States, and we are pleased to be partnered with a group of committed physician-investigators in this effort,” said Brian Ward, Ph.D., diaDexus’ president and chief executive officer. “The PLAC Test for Lp-PLA 2 Activity is already on the market in Europe where customers value the substantial benefits of improved productivity due to automation and far simpler sample handling. Our goal is to achieve FDA clearance to be able to offer these same product benefits to our U.S. customers.”

The company’s PLAC Tests are simple blood tests that uncover the hidden risk of heart attack by measuring Lp-PLA 2, a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque. Lp-PLA 2 levels aid in cardiovascular disease risk assessment independent from other biomarkers—providing distinct insight into the relationship among inflammation, atherosclerosis and cardiovascular outcomes. The PLAC Tests support preventive medicine by providing physicians with a way to uncover the risk of heart attack beyond standard lipid measurements, such as cholesterol testing.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA 2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for Lp-PLA 2 Activity on-site. For more information, please visit the company's website at

Forward-Looking Statements

This release contains forward-looking statements based on current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include whether the PLAC Test for Lp-PLA 2 Activity can achieve FDA clearance and if even if cleared, the ability to gain acceptance in the marketplace; and the timing of data from the partnered longitudinal cardiovascular disease study. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent quarterly report on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at The information set forth herein speaks only as of the date hereof, and except as required by law, diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.05 -1.30%
FB $99.88 -1.10%
GOOG $674.61 -1.40%
TSLA $152.84 6.40%
YHOO $26.37 -2.70%


Chart of I:DJI
DOW 15,547.80 -366.94 -2.31%
S&P 500 1,816.86 -35.00 -1.89%
NASDAQ 4,232.2020 -51.39 -1.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs